We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-10.55%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$353M
AUM Growth
-$40.7M
Cap. Flow
+$13.6M
Cap. Flow %
3.86%
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$4.3M
2
STOK icon
Stoke Therapeutics
STOK
+$2.54M
3
DNLI icon
Denali Therapeutics
DNLI
+$2.45M
4
INGN icon
Inogen
INGN
+$2.35M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$2.12M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$3.28M
2
AXGN icon
Axogen
AXGN
+$3M
3
ATRC icon
AtriCure
ATRC
+$1.83M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$877K
5
ALKS icon
Alkermes
ALKS
+$864K

Sector Composition

Rank Sector Weight
1 Healthcare 85.64%
2 Miscellaneous 14.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$32.8M 9.3%
404,505
+7,000
+2% +$626K
STXS icon
2
Stereotaxis
STXS
$145M
$24.1M 6.83%
13,680,554
– –
RVMD icon
3
Revolution Medicines
RVMD
$44.6B
$23.2M 6.58%
656,176
+25,000
+4% +$1.01M
MRUS
4
DELISTED
Merus
MRUS
$19.4M 5.51%
461,804
+10,000
+2% +$436K
ATRC icon
5
AtriCure
ATRC
$2.47B
$19.1M 5.42%
592,273
-49,400
-8% -$1.83M
CYTK icon
6
Cytokinetics
CYTK
$10B
$16M 4.54%
398,100
– –
BPMC
7
DELISTED
Blueprint Medicines
BPMC
$13.5M 3.82%
152,263
+2,500
+2% +$244K
IBB icon
8
iShares Biotechnology ETF
IBB
$10.5B
$13.1M 3.72%
102,500
– –
AXGN icon
9
Axogen
AXGN
$2.77B
$12.6M 3.57%
680,782
-166,100
-20% -$3M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.3B
$12.5M 3.55%
80,398
-22,957
-22% -$3.28M
IDYA icon
11
IDEAYA Biosciences
IDYA
$3.87B
$9.65M 2.74%
589,330
+90,503
+18% +$1.93M
XENE icon
12
Xenon Pharmaceuticals
XENE
$5.81B
$9.18M 2.6%
273,739
– –
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$8.68M 2.46%
752,359
-59,319
-7% -$605K
NBIX icon
14
Neurocrine Biosciences
NBIX
$15.7B
$7.92M 2.25%
71,615
– –
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.74B
$6.69M 1.9%
544,502
+2,500
+0.5% +$35.3K
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
$5.8M 1.64%
731,363
– –
TNDM icon
17
Tandem Diabetes Care
TNDM
$1.49B
$5.64M 1.6%
294,208
+71,000
+32% +$2.08M
URGN icon
18
UroGen Pharma
URGN
$2.13B
$5.45M 1.54%
492,515
– –
BHVN icon
19
Biohaven
BHVN
$2.33B
$5.29M 1.5%
220,235
– –
MLYS icon
20
Mineralys Therapeutics
MLYS
$2.26B
$4.91M 1.39%
309,200
+162,700
+111% +$1.87M
RCUS icon
21
Arcus Biosciences
RCUS
$3.72B
$4.91M 1.39%
625,126
+370,909
+146% +$4.3M
DXCM icon
22
DexCom
DXCM
$34.3B
$4.48M 1.27%
65,552
– –
BCRX icon
23
BioCryst Pharmaceuticals
BCRX
$2.51B
$4.19M 1.19%
558,255
-108,745
-16% -$877K
EWTX icon
24
Edgewise Therapeutics
EWTX
$4.64B
$4.03M 1.14%
183,140
-4,000
-2% -$105K
LKFT
25
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.27M 0.93%
130,175
– –
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, DAFNA Capital Management held 90 positions worth $353M, down 10% from $393M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

DAFNA Capital Management deployed $13.6M of net new capital in Q1 2025, opening 8 new positions and adding to 24 existing holdings. Its largest new stake was Denali Therapeutics: 127,900 shares worth $1.74M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $3.28M trimmed.

  • DAFNA Capital Management's largest Q1 2025 buy was Denali Therapeutics: 127,900 shares worth $1.74M.
  • DAFNA Capital Management added most to Arcus Biosciences in Q1 2025, an estimated $4.3M increase.
  • DAFNA Capital Management's biggest Q1 2025 reduction was Ascendis Pharma A/S, cutting an estimated $3.28M.
  • DAFNA Capital Management fully exited Centessa Pharmaceuticals in Q1 2025, selling an estimated $795K.
  • DAFNA Capital Management's ten largest holdings make up 53% of its $353M portfolio in Q1 2025.
  • DAFNA Capital Management opened 8 new positions and closed 7 in Q1 2025.
  • DAFNA Capital Management's portfolio value fell 10% quarter-over-quarter to $353M.

Based on DAFNA Capital Management's 13F filing for Q1 2025, filed 15 May 2025.